From the British Heart Foundation Cardiovascular Research Centre (J.J.V.M.) and the Robertson Centre for Biostatistics (N.G.), University of Glasgow, Glasgow, United Kingdom; Centre of Cardiovascular Research and Education in Therapeutics, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia (H.K.); the Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, Ohio State University, Columbus (W.T.A.); Stavanger University Hospital, Stavanger, and the Institute of Internal Medicine, University of Bergen, Bergen - both in Norway (K.D.); Rigshospitalet Copenhagen University Hospital, Copenhagen (L.V.K.); the Cardiovascular Division, Brigham and Women's Hospital, Boston (A.S.D., S.D.S.); Novartis Pharma, Basel, Switzerland (M.A.A., Y.C., Q.S., G.T.); and the University of California, San Francisco, San Francisco (B.M.M.).